The Role of Urinary RhoA, NGF, and BDNF Levels in Overactive Bladder and Vitamin D Deficiency
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Urotherapy.
- Who it may be relevant to
- Registry conditions: Overactive Bladder, Vitamin D Deficiency. Basic parameters: up to 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Turkey (Türkiye)
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Role of Urinary RhoA, NGF, and BDNF Levels in Diagnosis and Follow-up in Children With Overactive Bladder and Vitamin D Deficiency.
Overview
The primary aim of this study is to evaluate the role of three specific urinary proteins-RhoA, Nerve Growth Factor (NGF), and Brain-Derived Neurotrophic Factor (BDNF)-as potential biomarkers for the diagnosis and follow-up of children aged 4-18 diagnosed with Overactive Bladder (OAB) and Vitamin D deficiency.
Interventions
- Behavioral Urotherapy
Diagnosis and first-line treatment (urotherapy) will be conducted per European Association of Urology (EAU) guidelines.
Primary outcome measures
- Changes in Urinary Biomarker Levels: * Quantitative measurement of urinary RhoA, NGF (Nerve Growth Factor), and BDNF (Brain-Derived Neurotrophic Factor) levels using the ELISA method. [Time frame: One year]
Secondary outcome measures (1)
- Clinical Symptom Improvement: * Reduction in LUTS (Lower Urinary Tract Symptoms) based on standardized voiding dysfunction symptom scores. [Time frame: One year]
Eligibility criteria
Inclusion criteria
- Children aged 4-18 years presenting with active OAB symptoms (frequency, urgency)
Exclusion criteria
- Neurological diseases
- Malignancy
- Active urinary tract infections
- Anatomical bladder anomalies
- History of prior OAB treatment/urological surgery.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Diagnostic
Study locations
Turkey (Türkiye) · 1 center
- Marmara University School of Medicine Urology Department — Pendik
Identifiers
NCT: NCT07513363 · MAR.UAD.0031